Recombinant human interleukin-11 for chemotherapy-induced thrombocytopenia of acute leukemia: a multi-center study
10.3760/cma.j.issn.1009-9921.2018.05.005
- VernacularTitle: 重组人白细胞介素11治疗急性白血病化疗所致血小板减少的多中心研究
- Author:
Xinyu CUI
1
;
Hong ZHOU
2
;
Yinghua LI
3
;
Li ZHENG
4
;
Lian BAI
5
;
Na LIU
2
;
Yanzhang QU
2
;
Libo JIANG
2
;
Sanjun CHEN
6
Author Information
1. Department of Hematology, the Third Affiliated Hospital of Qiqihar Medical University, Qiqihar 161000, China
2. Department of Hematology, the Second Affiliated Hospital of Qiqihar Medical University, Qiqihar 161006, China
3. Department of Hematology, the First Affiliated Hospital of Harbin Medical University, Harbin 150001, China
4. Department of Hematology, the Guangyuan Central Hospital, Guangyuan 628000, China
5. Department of Hematology, Canglang Hospital of Suzhou, Suzhou 215000, China
6. Department of Hematology, the Second Affiliated Hospital of Nanchang University, Nanchang 330000, China
- Publication Type:Journal Article
- Keywords:
Leukemia, acute;
Thrombocytopenia;
Interleukin-11
- From:
Journal of Leukemia & Lymphoma
2018;27(5):276-279
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the efficacy and safety of recombinant human interleukin-11 (rhIL-11) in treatment of chemotherapy-induced thrombocytopenia of acute leukemia.
Methods:Acute leukemia patients with chemotherapy-induced thrombocytopenia [Platelets (Plt) < 50×109/L] in 6 centers nationwide from February 2016 to July 2016 were treated with rhIL-11 (2 mg/time, twice per day) by subcutaneous injection. Treatment lasted 7 days or at least until Plt≥ 50×109/L. The Plt recovery was observed during treatment.
Results:A total of 112 patients were enrolled, and 2 patients decided to drop out of study. The efficacy population consisted of 110 patients, and the total response rate reached 74.5% (82/110). The average variation of Plt during treatment was (70±54)×109/L, and recovery average time of Plt for the patients with favorable efficacy was (8.7±3.0) days. In treatment with severe thrombocytopenia, rhIL-11 alone could shorten the recovery time compared with rhIL-11 combined with Plt transfusion [(8.0±2.6) d vs. (9.6±3.5) d, t=2.17, P=0.03].
Conclusion:rhIL-11 twice a day of subcutaneous injection can effectively promote Plt recovery and reduce Plt transfusion with less adverse reactions, which is worthy of further application.
